Results 31 to 40 of about 16,276 (198)

Upper gastrointestinal lesions in patients receiving clopidogrel anti-platelet therapy

Journal of the Formosan Medical Association, 2012
Clopidogrel is associated with a high incidence of upper gastrointestinal bleeding in high-risk patients. However, the characteristic upper gastrointestinal lesions in symptomatic clopidogrel users remain unclear.
Tzung-Jiun Tsai, Kwok-Hung Lai, Ping-I. Hsu, Chiun-Ku Lin, Hoi-Hung Chan, Hsien-Chung Yu, Huay-Min Wang, Kung-Hung Lin, Kai-Ming Wang, Shiuh-Nan Chang, Chun-Peng Liu, Shin-Hung Hsiao, Hung-Ru Huang, Ching-Huang Lin, Feng-Woei Tsay   +14 more
doaj   +1 more source

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective.
Cinzia Dello Russo, Iain Frater, Rebecca Kuruvilla, Stefanie Lip, Hannah O'Neill, Kerry Burke, Vicky Chaplin, Alexander S. F. Doney, Salim Elyas, Nicholas Greaves, Sophie Harding, David Hargroves, Judith Hayward, Dyfrig A. Hughes, Tom A. T. Hughes, Sree Kondapally, Patrick Mok, Aaron Peace, Imran Rafi, Simon Ray, Vicky Stinton, Luigi Venetucci, Munir Pirmohamed   +22 more
wiley   +1 more source

Radial capacity and hemodynamics evaluation in vitro and implantable feasibility validation in vivo of thinner bioresorbable polymer vascular stents

BMEMat, EarlyView.
A series of in vitro experiments, numerical simulations and in vivo experiments were conducted to jointly evaluate the effects of different thicknesses of bioabsorbable polymer vascular stents on their radial capacity, hemodynamics and in vivo outcomes.
Chong Chen, Tao Li, Zhongyou Li, Jingyuan Zhou, Zhuo Zhang, Yan Xiong, Rifang Luo, Yu Chen, Yunbing Wang, Ping Fu   +9 more
wiley   +1 more source

Evaluation of clopidogrel response with light transmission aggregometry before extra- intracranial stenting

Ендоваскулярна нейрорентгенохірургія, 2020
Objective – to study the result of light transmission aggregometry with ADP for platelet reactivity before and after clopidogrel administration before extra-intracranial stenting. Materials and methods.
D.V. Shchehlov, M.B. Vyval, V.P. Khlopenova, S.M. Konobas   +3 more
doaj   +1 more source

P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes

Journal of Interventional Cardiology, 2023
Background. Randomized trials have shown superiority of the novel P2Y12 inhibitors over clopidogrel in patients with acute coronary syndrome (ACS), but clinical benefit in the community remains controversial.
Amit Sachdeva, Ratnabhushan Mutyala, Neha Mantri, Shiyun Zhu, Edward McNulty, Matthew Solomon   +5 more
doaj   +1 more source

Endovascular Stenting for Pulmonary Vein Stenosis Following Atrial Fibrillation Ablation: From Diagnosis to Intervention

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Pulmonary vein stenosis (PVS) is an uncommon but serious complication of atrial fibrillation (AF) ablation, often misinterpreted as primary pulmonary disease. Timely identification is essential to prevent irreversible injury and to guide appropriate referral for interventional management. Case Presentations Through the discussion of
Cristina Aurigemma, Marco Busco, Francesco Bianchini, Gabriella Locorotondo, Francesca Graziani, Annalisa Pasquini, Enrico Romagnoli, Mattia Lunardi, Lazzaro Paraggio, Francesco Varone, Andrea Smargiassi, Bruno Iovene, Riccardo Marano, Carlo Trani, Francesco Burzotta   +14 more
wiley   +1 more source

Abrupt Cessation of One-Year Clopidogrel Treatment Is Not Associated With Thrombotic Events

Journal of Pharmacological Sciences, 2011
.: We aimed to examine the rate of thrombotic events after discontinuation of one year clopidogrel therapy in patients with implanted coronary stent, and to determine platelet aggregability by multiple electrode analyzer after cessation of clopidogrel ...
Nina Djukanovic, Zoran Todorovic, Slobodan Obradovic, Danijela Zamaklar-Trifunovic, Srdjana Njegomirovic, Nataša M. Milic, Milica Prostran, Miodrag Ostojic   +7 more
doaj   +1 more source

Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. [PDF]

PLoS ONE, 2014
Clopidogrel is an antiplatelet prodrug that is recommended to reduce the risk of recurrent thrombosis in coronary artery disease (CAD) patients. Paraoxonase 1 (PON1) is suggested to be a rate-limiting enzyme in the conversion of 2-oxo-clopidogrel to ...
Damrus Tresukosol, Bhoom Suktitipat, Saowalak Hunnangkul, Ruttakarn Kamkaew, Saiphon Poldee, Boonrat Tassaneetrithep, Atip Likidlilid   +6 more
doaj   +1 more source

Model‐Informed Drug Development for Daprodustat Supports the Design of Individualized Dosing Regimens in Chronic Kidney Disease Patients With Anemia

Clinical Pharmacology &Therapeutics, EarlyView.
Model‐informed drug development (MIDD) played a crucial role in the successful development and regulatory approval of daprodustat, a novel oral hypoxia‐inducible factor prolyl hydroxylase (HIF‐PHI) inhibitor aimed at treating anemia in chronic kidney disease patients.
Kelly M. Mahar, Shuying Yang, Brendan Johnson, Sandra A.G. Visser, Paul van den Berg, Martijn van Noort, Teun M. Post   +6 more
wiley   +1 more source

Clopidogrel, a P2Y12 receptor antagonist, potentiates the inflammatory response in a rat model of peptidoglycan polysaccharide-induced arthritis.

PLoS ONE, 2011
The P2Y12 receptor plays a crucial role in the regulation of platelet activation by several agonists, which is irreversibly antagonized by the active metabolite of clopidogrel, a widely used anti-thrombotic drug.
Analia E Garcia, Sripal R Mada, Mario C Rico, Raul A Dela Cadena, Satya P Kunapuli   +4 more
doaj   +1 more source